Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

131
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
131
Crossover Experiments01:16

Crossover Experiments

2.7K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
2.7K
Two-Compartment Open Model: Extravascular Administration01:12

Two-Compartment Open Model: Extravascular Administration

137
The two-compartment model for extravascular administration represents a drug's absorption and distribution process. It features a central compartment, where the drug is first absorbed, and a peripheral compartment, which illustrates the drug's distribution throughout the body. The rate of change in drug concentration in the central compartment is calculated by three exponents: absorption, distribution, and elimination.
The absorption exponent (ka) indicates the speed at which the drug...
137
Actuarial Approach01:20

Actuarial Approach

57
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
57
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

80
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
80
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation01:24

One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation

371
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
371

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Society of Contact Dermatitis Guideline for Diagnostic Patch Testing-Recommendations on Best Practice (Update 2026).

Contact dermatitis·2026
Same author

SPIRIT 2025 statement: updated guideline for protocols of randomised trials.

Lancet (London, England)·2026
Same authorSame journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
Same author

Sample Size Calculation for the ROCI Design.

Statistics in medicine·2026
Same author

Bayesian analysis in confirmatory clinical trials: A narrative review and discussion of current practice.

Clinical trials (London, England)·2026
Same author

Adjusting for confounding in population administrative data when confounders are only measured in a linked cohort.

International journal of population data science·2026
Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026
Same journal

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026
Same journal

Will the Pharmaceutical Industry Need Statisticians in an AI World?

Pharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: May 29, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K

New Methods for Two-Stage Treatment Switching Estimation.

Dan Jackson1, Di Ran2, Fanni Zhang2

  • 1AstraZeneca, Cambridge, UK.

Pharmaceutical Statistics
|February 5, 2025
PubMed
Summary
This summary is machine-generated.

This study introduces new methods for analyzing cancer treatment trials where patients switch therapies. It helps estimate treatment effects more accurately, even with common treatment switching, aiding healthcare decisions.

Keywords:
counterfactualscrossovermultiple imputationssurvival analysis

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.6K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.4K

Related Experiment Videos

Last Updated: May 29, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.6K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.4K

Area of Science:

  • Oncology
  • Biostatistics
  • Clinical Trials

Background:

  • Treatment switching is frequent in oncology clinical trials, complicating the estimation of treatment effects.
  • Control group patients often receive the experimental treatment as a subsequent therapy, posing analytical challenges.

Purpose of the Study:

  • To define and estimate novel treatment effect estimands that account for varying proportions of treatment switching.
  • To adapt two-stage estimation methods for these new estimands using a secondary baseline.
  • To facilitate decision-making in universal healthcare systems by providing robust treatment effect estimates.

Main Methods:

  • Defined precise estimands for treatment effects under different switching proportions.
  • Utilized the time of first subsequent treatment as a secondary baseline.
  • Developed propensity score methods for confounding adjustment at the secondary baseline.
  • Introduced a novel quantile matching technique for post-secondary baseline survival modeling.

Main Results:

  • The proposed secondary baseline and estimation methods are easily defined and widely applicable.
  • The methodology allows for the estimation of alternative treatment effect estimands.
  • The approach was successfully motivated by a real-world immuno-oncology trial.

Conclusions:

  • The developed methodology enhances the accurate estimation of treatment effects in the presence of treatment switching.
  • This work provides valuable tools for decision-making in healthcare, particularly in immuno-oncology.
  • The flexible estimation framework accommodates various post-secondary baseline survival models.